Analyst Price Targets — CRSP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 17, 2026 1:33 pm | — | Morgan Stanley | $33.00 | $52.25 | TheFly | Crispr Therapeutics price target raised to $33 from $32 at Morgan Stanley |
| February 14, 2026 11:41 am | Geulah Livshits | Chardan Capital | $76.00 | $53.07 | TheFly | Crispr Therapeutics price target raised to $76 from $74 at Chardan |
| February 13, 2026 2:04 pm | — | Needham | $82.00 | $53.89 | TheFly | Crispr Therapeutics price target raised to $82 from $80 at Needham |
| February 13, 2026 2:02 pm | — | Evercore ISI | $74.00 | $53.81 | TheFly | Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI |
| November 26, 2025 10:12 am | — | Chardan Capital | $74.00 | $52.79 | TheFly | Crispr Therapeutics price target lowered to $74 from $82 at Chardan |
| November 11, 2025 9:24 am | Luca Issi | RBC Capital | $50.00 | $54.58 | StreetInsider | CRISPR Therapeutics (CRSP) PT Raised to $50 at RBC Capital |
| October 13, 2025 11:33 am | Yanan Zhu | Wells Fargo | $75.00 | $73.10 | TheFly | Crispr Therapeutics price target raised to $75 from $65 at Wells Fargo |
| February 3, 2025 11:11 am | Mitchell Kapoor | H.C. Wainwright | $65.00 | $40.00 | TheFly | Crispr Therapeutics initiated with a Buy at H.C. Wainwright |
| November 6, 2024 11:15 am | Jay Olson | Oppenheimer | $95.00 | $49.51 | StreetInsider | Oppenheimer Reiterates Outperform Rating on CRISPR Therapeutics (CRSP) |
| November 5, 2024 8:25 pm | Rick Bienkowski | Leerink Partners | $67.00 | $50.36 | StreetInsider | CRISPR Therapeutics (CRSP) PT Lowered to $67 at Leerink Partners |
Latest News for CRSP
CRISPR obtained approval for Casgevy back in 2023, but the rollout has been slow. In 2025, the company incurred a loss of more than $580 million.
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
The Ark Innovation ETF is Cathie Wood's flagship fund and is heavily weighted toward innovative growth bets. The ETF recently purchased Figma, CRISPR Therapeutics, and CoreWeave.
CRISPR Therapeutics AG (NASDAQ: CRSP - Get Free Report) General Counsel James Kasinger sold 2,112 shares of the business's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $52.58, for a total value of $111,048.96. Following the completion of the sale, the general counsel owned 85,115
The past few years have been challenging for the biotech.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.